Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 30, 2007

Canadian Organizations to Investigate ViRexx’ Vaccine Platform Technology

  • ViRexx Medical inked deals with the Canada's National Research Council National Institute for Nanotechnology (NRC-NINT) and Defence Research and Development Canada (DRDC) Suffield.

    "These research collaborations were supported through network and financial contributions from NRC-IRAP (Industrial Research Assistance Program), which provide us with the opportunity to explore multiple uses of our Chimigen Vaccine platform technology and establish its efficacy as an adaptable platform technology in nanoparticle and biodefence applications," comments Peter Smetek, interim CEO and chairman of the board of directors of ViRexx Medical.

    Researchers at NINT will investigate the physical characteristics and immunological and nanoparticle forming properties of the company’s Chimigen™ vaccine. Scientists at DRDC Suffield will continue to study the Chimigen Vaccine platform for biodefense applications.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »